iQX Limited (NSX:IQX) today announced it has received a worldwide license from Harvard s Office of Technology Development to commercialise diagnostic technology developed at the Wyss Institute for Biologically Inspired Engineering at Harvard University.
iQX Limited (NSX:IQX) is pleased to announce that OncoTEX Inc has received licensing for a gold compound platform technology that induces the body s immune system to destroy cancer cells.
A member of The iQ Group Global, iQX Limited is an investment funds management company specialising in the bioscience sector that is committed to eradicating disease through capital investment.
IQX Limited (NSX:IQX) Progress of Clinical Programs
Progress of Clinical ProgramsSydney, April 29, 2021 AEST (ABN Newswire) - iQX Limited (iQX Ltd) (
NSX:IQX) would like to announce that Life Science Biosensor Diagnostics Pty Ltd (LSBD) in which iQX Ltd holds a 19% equity position, has received approval from the Harvard Longwood campus Institutional Review Board (IRB) to commence a clinical validation study to test patient samples from a COVID-19 repository. The study follows a partnership with the Wyss Institute for Biologically Inspired Engineering at Harvard University (Wyss Institute), through Life Science Biosensor Diagnostics Pty Ltd subsidiary, GBS Inc. (
Nasdaq:GBS), a Delaware corporation, to develop a novel diagnostic SARS-CoV-2 test.